Alto misses primary efficacy endpoint in phase 2 depression trial
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo. Still, the biotech pointed to other outcomes to make the case for the molecule.
Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on placebo. Still, the biotech pointed to other outcomes to make the case for the molecule.
